Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-4528 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT05840224Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 1, open-label trial of GS-4528 in solid tumor (3 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 24 months, Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) up to 4 weeks and 1 more. Started May 2023; status: active, not recruiting.
02
Drugs
GS-4528
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05840224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840224.